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Abstract: The eIF4F complex is a translation initiation factor that closely regulates translation in
response to a multitude of environmental conditions including viral infection. How translation
initiation factors regulate rotavirus infection remains poorly understood. In this study, the
knockdown of the components of the eIF4F complex using shRNA and CRISPR/Cas9 were performed,
respectively. We have demonstrated that loss-of-function of the three components of eIF4F, including
eIF4A, eIF4E and eIF4G, remarkably promotes the levels of rotavirus genomic RNA and viral protein
VP4. Consistently, knockdown of the negative regulator of eIF4F and programmed cell death protein
4 (PDCD4) inhibits the expression of viral mRNA and the VP4 protein. Mechanically, we confirmed
that the silence of the eIF4F complex suppressed the protein level of IRF1 and IRF7 that exert potent
antiviral effects against rotavirus infection. Thus, these results demonstrate that the eIF4F complex is
an essential host factor restricting rotavirus replication, revealing new targets for the development of
new antiviral strategies against rotavirus infection.
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1. Introduction
Rotavirus is considered to be one of leading causative agent of severe diarrhea in infants younger
than five years old [1], and it causes estimated 215,000 deaths in children each year globally [2].
Although rotavirus infection mainly occurs in low-income countries [3], it also inflicts a heavy burden
in industrialized countries. For example, in the European Union, rotavirus infection causes more than
200 deaths, over 87,000 hospital admissions, and almost 700,000 outpatient visits in children younger
than five years of age annually [4]. Emerging evidence indicates that rotavirus infection causes severe
complications in organ transplant patients irrespective to their ages [5]. Although vaccines have been
developed, no approved antiviral treatment is available.
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The genome of rotavirus contains 11 segments encoding 12 proteins including six structural
(VP1-4, VP6, and VP7) and six non-structural proteins (NSP1-6) [6]. Among the structural proteins,
as a spike protein, rotavirus VP4 plays an essential role in both viral entry and exit [7]. VP4 was also
demonstrated to be of importance in viral attachment and internalization [8], which is often used for
the development of rotavirus vaccines [8]. VP4 contains two subunits including a C-terminal subunit
VP5* and a N-terminal subunit VP8*, and both VP5* and VP8* help virus entry by interacting with
several putative partners and cell surface receptors [7]. The rotavirus genome is a double-strand RNA
containing a cap at 5′ untranslated regions (UTR) synthesized by the viral transcriptase but lacks
a polyadenylated tail instead having a consensus sequence at 3′ UTR [9]. It has been reported that
rotavirus NSP3 is able to bind to the 3′ consensus sequence of viral mRNA and interact with eIF4G to
aid translation of viral mRNA [10]. Rotavirus NSP3 stabilizes the eIF4E–eIF4G interaction to exert an
enhanced effect on the translation of both poly (A)- and non-poly (A)-tailed mRNAs [11].
There are three phases in protein synthesis including initiation, elongation, and termination [11].
Initiation determines translation rates [12]. Most of the eukaryotic mRNAs are characterized by a
m7GpppX structure (where m7Gppp is the 7-methyl-guanosine-containing and X is any nucleotide),
termed as a cap, at the 5′ ends and the poly (A) tail at the 3′ end [13]. The mRNA containing a cap
at the 5′ ends is able to be more efficiently translated than that lacking this structure [14], and these
mRNAs are translated in a cap-dependent manner [12]. The cap structure is bound by the eukaryotic
translation initiation factor 4F (eIF4F) which is a protein complex containing three constituent proteins:
a eukaryotic translation initiation factor 4A (eIF4A), a eukaryotic translation initiation factor 4E (eIF4E),
and a eukaryotic translation initiation factor 4G (eIF4G) [15]. The eIF4F complex plays a pivotal role
in cap-dependent mRNA protein translation initiated by recruiting mRNA to a ribosome [13]. As
an RNA helicase, eIF4A makes use of ATP hydrolysis to unwind and resolve the RNA secondary
structure [16]. The eIF4E recognizes and binds to the 7-methylguanosine (m7G) cap located at the
5′-UTRs of mRNA to mediate the mRNA recruitment on ribosomes, thus initiating the translation
together with other initiation factors [17]. As a scaffold protein, eIF4G plays a central role in translation
initiation by assembling eIF4E and eIF4A to further form the eIF4F complex [18]. The programmed cell
death protein 4 (PDCD4) is a translation suppressor of mRNAs by interacting with eIF4A to suppress
its helicase activity [19]. As a downstream target of mechanistic target of the rapamycin (mTOR)
pathway, the phosphorylation of protein kinase S6K1 is able to phosphorylate PDCD4 to release it from
eIF4A, thus allowing eIF4A to interact with eIF4G to form the eIF4F complex, followed by initiating
translation [20].
Viruses require components from the host cell to replicate, assemble viral components, and
release their new synthesized virions [14]. Viral protein synthesis completely relies on the translational
machinery of the host due to viruses lacking this machinery themselves [21]. Viruses are able to exploit
the translational machinery, including eIF4F, to support the translation of their transcripts [15]. Certain
mammalian viruses are involved in targeting the eIF4F complex to regulate both viral and host mRNA
translation; while many RNA viruses inhibit host protein synthesis to initiate the translation of their
own mRNAs by inhibiting eIF4F [22]. Feline calicivirus (FCV) and mouse norovirus (MNV) have
been reported to be capable of directly interacting with eIF4E, and viral RNA translation requires the
eIF4A, indicating that the replication of the two viruses requires eIF4F [23]. Blocking eIF4E–eIF4G
interaction has been demonstrated to cause inhibition of coronavirus replication, indicating that eIF4F
has a promoting effect on the virus replication [24]. Furthermore, certain members of the eIF4G family
were thought to be able restrict the infection of Rice yellow mottle virus (RYMV) [25]. Thus, the eIF4F
complex has different effects on distinct viruses.
The eIF4F complex plays an essential role in regulating interferon signaling which is considered to
be the first line of antiviral defense [26]. The phosphorylation of eIF4E was reported to exert antiviral
effect via regulating the production of type I interferon [27]. It was found that the eIF4F complex could
tightly regulate the translation of the signal transducer and activator of transcription 1 (STAT1) mRNA
that plays a crucial role in type I interferon signaling [28]. Thus, in this study, we have dissected
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the effects of the cellular translation machinery, the eIF4F complex, on rotavirus infection, and we
found that the eIF4F complex is an essential host factor in counteracting rotavirus infection through
regulating the antiviral protein IRF1 and IRF7.
2. Results
2.1. The eIF4A Inhibits Rotavirus Infection
We first examined the effects of rotavirus infection on the expression of the components of the
eIF4F complex, including eIF4A and eIF4E, at indicated time points (1, 2, 4, 6, 24, and 48 h). Although
rotavirus infection did not affect the protein expression of the eIF4F complex (Supplementary Figure
S1), it is interesting to investigate whether the components of the eIF4F complex regulate the course
of the rotavirus infection. To this aim, we first detected the effects of eIF4A on rotavirus infection,
by performing a lentiviral RNAi-mediated loss-of-function assay to silence the eIF4A gene. All five
short hairpin RNA (shRNA) vectors showed successful knockdown (Figure 1A,B). Importantly, two
shRNA vectors (No 1 and 2) resulted in a 121.7 ± 60.6 (n = 6, P < 0.01)- and 56.7 ± 29.9 (n = 6, P < 0.01)-
fold increase in SA11 rotavirus mRNA, respectively (Figure 1C). All shRNA vectors showed no clear
cytotoxicity determined by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT)
assay (Supplementary Figure S2A). Western blot indicated that all five shRNA vectors increased the
rotavirus VP4 protein level (Figure 1D). To further verify these findings, we used CRISPR/Cas9 to
knockout the eIF4A gene in Caco2 cells (Figure 1E). After eIF4A knockout, the viral mRNA and protein
levels were remarkably reduced (Figure 1F,G).Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 4 of 15 
 
 
Figure 1. Knockdown of eIF4A supports rotavirus infection. (A) Western blot assay detected eIF4A in 
Caco2 cells transduced with lentiviral RNAi vectors against eIF4A. (B) Successful knockdown by 
shRNA vectors measured by RT-qPCR (n = 6, **P < 0.01, Mann–Whitney test). (C) Silence of eIF4A 
increased rotavirus genomic RNA level (n = 6, *P < 0.05, **P < 0.01, Mann–Whitney test). (D) Silence 
of eIF4A increased viral VP4 protein level in SA11 rotavirus infected Caco2 cells. (E) Western blot 
detected the eIF4A protein level in Caco2 cells transduced with CRIPSRs against eIF4A, suggesting a 
successful knockout. (F) Silence of eIF4A by CRISPR/Cas9 increased the rotavirus genomic RNA level 
(n = 6, *P < 0.05, Mann–Whitney test). (G) Silence of eIF4A by CRISPR/Cas9 increased the viral VP4 
protein level in SA11 rotavirus infected Caco2 cells. 
2.2. Blocking eIF4E Promotes Rotavirus Infection 
Another component of the eIF4F complex, eIF4E, is responsible for binding to the cap of mRNA. 
Similarly, a lentiviral RNAi-mediated loss-of-function assay was performed to silence the eIF4E gene 
to assess its effect on rotavirus infection. One out of the four shRNAs exerted a potent knockdown 
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Figure 1. Knockdown of eIF4A supports rotavirus infection. (A) Western blot assay detected eIF4A
in Caco2 cells transduced with lentiviral RNAi vectors against eIF4A. (B) Successful knockdown by
shR vectors measured by RT-qPCR (n = 6, ** P < 0.01, Mann–Whitney test). (C) Silence of eIF4A
increas t irus genomic RNA l vel (n = 6, * P < 0.05, ** P < 0.01, Man –Whitney test). (D) Silence
of eIF reased viral VP4 protein level in SA11 rotavirus infected Caco2 cells. (E) Western blot
detect t eIF4A protein l vel in Caco2 cells trans uced with CRIPSR against eIF4A, suggesting a
successful knockout. (F) Silence of eIF4A by CRISPR/Cas9 increased the rotavirus genomic RNA level
(n = 6, * P < 0.05, Mann–Whitney test). (G) Silence of eIF4A by CRISPR/Cas9 increased the viral VP4
protein level in SA11 rotavirus infected Caco2 cells.
2.2. Blocking eIF4E Promotes Rotavirus Infection
Another component of the eIF4F complex, eIF4E, is responsible for binding to the cap of mRNA.
Similarly, a lentiviral RNAi-mediated loss-of-function assay was performed to silence the eIF4E gene to
assess its effect on rotavirus infection. One out of the four shRNAs exerted a potent knockdown effect
on eIF4E (Figure 2A). Consistently, this shRNA vector resulted in a 14.5 ± 5.8 (n = 6, P < 0.01)-fold
increase in SA11 rotavirus mRNA (Figure 2B). All shRNA vectors showed no clear cytotoxicity
measured by MTT assay (Supplementary Figure S2B). This shRNA vector resulted in the increase in
the SA11 rotavirus VP4 protein level (Figure 2C). To further verify this, we used CRISPR/Cas9 to
knockout eIF4E in Caco2 cells (Figure 2D). After eIF4E gene knockout, the viral RNA and protein
levels were restricted (Figure 2E,F).
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As a scaffolding protein, eIF4G protein is able to physically link mRNA and the small ribosomal 
subunit via protein-protein interactions. To investigate the effects of eIF4G protein on rotavirus 
infection, a lentiviral shRNA-mediated loss-of-function assay was conducted, which resulted in gene 
silence of eIF4G by all five shRNA vectors at both the mRNA and protein level (Figure 3A,B). 
Importantly, all these shRNA vectors resulted in a potent increase in the viral RNA and protein level 
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Figure 2. The eIF4E suppresses rotavirus infection. (A) Western blot assay measured the eIF4E protein
in Caco2 cells transduced lentiviral RNAi vectors against eIF4E, indicating that one out of three shRNA
vectors exerted a potent knockdown. (B) The knockdown of eIF4E significantly promoted rotavirus
genomic RNA (n = 6, ** P < 0.01, Mann–Whitney test). (C) Western blot assay confirmed that eIF4E
knockdown increased rotavirus protein level. (D) The eIF4E was knocked out by CRISPR/Cas9 assay.
(E) Silence of eIF4E by CRISPR/Cas9 increased the rotavirus RNA level (n = 6, * P < 0.05, Mann–Whitney
test). (F) Silence of eIF4E by CRISPR/Cas9 increased the rotavirus VP4 protein level.
2.3. The eIF4G Suppresses Rotavirus Infection
As a scaffolding protein, eIF4G protein is able to physically link mRNA and the small ribosomal
subunit via protein-protein interactions. To investigate the effects of eIF4G protein on rotavirus
infection, a lentiviral shRNA-mediated loss-of-function assay was conducted, which resulted in
gene silence of eIF4G by all five shRNA vectors at both the mRNA and protein level (Figure 3A,B).
Importantly, all these shRNA vectors resulted in a potent increase in the viral RNA and protein level
(Figure 3C,D). The vitality of cells was not affected by these shRNA vectors (Supplementary Figure
S2C). To further verify these findings, we performed a Crispr/cas9 assay to knockout eIF4G in Caco2
cells (Figure 3E). After gene knockout, the viral RNA and protein levels were inhibited (Figure 3F,G).
To further verify the effect of eIF4A, eIF4E, and eIF4G on rotavirus infection, CRIPRs against
eIF4A, eIF4E, and eIF4G were co-transfected in Caco2 cells. After puromycin selection, the knockout
of eIF4A, eIF4E, and eIF4G was detected by western blot, indicating successful knockout of three
genes (Figure 4A). The effect of eIF4A, eIF4E, and eIF4G on rotavirus infection was further detected
by RT-qPCR and western blot, demonstrating that both viral genomic RNA and viral protein VP4
synthesis were promoted (Figure 4B,C).Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 6 of 15 
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Figure 3. Silence of eIF4G promotes rotavirus infection. (A) Western blot assay detected eIF4G in Caco2
cells transduced with lentiviral RNAi vectors against eIF4G. (B) Successful knockdown by shRNA
vectors detected by RT-qPCR assay (n = 6, *** P < 0.001, Mann–Whitney test). (C) Silence of eIF4G
showed an increased rotavirus genomic RNA level (n = 6, * P < 0.05, ** P < 0.01, Mann–Whitney test).
(D) Silence of eIF4G promoted the viral VP4 protein level in SA11 rotavirus infected Caco2 cells. (E)
Western blot assay detected IF4G in Caco2 cells transduce with CRIPSRs against eIF4G. (F) Silence of
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promoted the rotavirus genomic RNA level detected by qPCR assay (n = 6, * P < 0.05, Mann–Whitney
test). (C) Silence of eIF4A/E/G showed increased rotavirus protein VP4.
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2.4. Programmed Cell Death Protein 4 (PDCD4) Promotes Rotavirus Infection
PDCD4 functions by inhibiting the translation by directly inhibiting the helicase activity of eIF4A
to competitively bind to the scaffold protein eIF4G. To further verify the effects of the eIF4F complex
on rotavirus infection, a lentiviral shRNA-mediated loss-of-function assay was performed to silence
PDCD4, which indicated that one out of three shRNA vectors (No 1) exerted a potent knockdown effect
(Figure 5A,B). Consistently, the shRNA vector resulted in a 50 ± 12 % (n= 8, P < 0.05)-fold reduction in
SA11 rotavirus mRNA (Figure 5C), and remarkable reduction in viral VP4 protein levels (Figure 5D).
All shRNA vectors have no significant cytotoxicity (supplementary Figure S2D).Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 8 of 15 
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Figure 5. Programmed cell death protein 4 (PDCD4) sustains rotavirus infection. (A) Western blot
assay detected PDCD4 in Caco2 cells transduced lentiviral RNAi vectors against PDCD4. (B) One
out of three shRNA vectors showed successful knockdown detected by RT-qPCR (n = 6, *** P < 0.001,
Mann–Whitney test). (C) Silence of PDCD4 showed inhibition of rotavirus genomic RNA levels (n = 8,
* P < 0.05, Mann–Whitney test). (D) Silence of PDCD4 inhibited viral VP4 protein level in SA11 rotavirus
infected Caco2 cells.
2.5. The eIF4F Complex Inhibits the Level of Antiviral Proteins to Exert Anti-Rotavirus Effect
To further explore the underlying molecular mechanism of the antiviral effects of the eIF4F
complex on rotavirus infection, we questioned the effect of the eIF4F complex on several antiviral
proteins including interferon regulatory factor 1 (IRF1), IRF7, and retinoic acid-inducible-I (RIG-I),
which indicated that the knockdown of eIF4A had no obvious effect on these antiviral proteins. While
the knockdown of eIF4E (shRNA No 2) was able to inhibit protein level of IRF1 and IRF7 (Figure 6B).
Knockdown of eIF4G was also capable of suppressing the protein level of IRF1 and IRF7 (Figure 6C).
To further verify this, the effect of IRF7 and IRF1 on rotavirus replication was detected, indicating that
knockout of either IRF7 (Figure 6D) or IRF1 (Figure 6F) could significantly reduce the genomic mRNA
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of SA11 rotavirus (Figure 6E,G). Thus, the antiviral effect against rotavirus of the eIF4F complex may
operate through regulating the expression antiviral proteins in the host.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 9 of 15 
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Figure 6. The eIF4F complex is required for IRF7 that exerts anti-rotavirus effect. (A) Western blot assay
detected the protein level of antiviral factors including IRF1, IRF7, and RIG-I in eIF4A knockdown
Caco2 cells. (B) Western blot assay detected the protein level of antiviral factors including IRF1, IRF7,
and RIG-I in eIF4E knockdown Caco2 cells. (C) Western blot assay detected the protein level of antiviral
factors including IRF1, IRF7, and RIG-I in eIF4G knockdown Caco2 cells. (D) Western blot assay
detected the protein level of IRF7 in eIF4G knockout Caco2 cells, and two out of four shRNA vectors
showed successful knockdown of IRF7 detected by western blot. (E) Silence of IRF7 increased rotavirus
genomic RNA level detected by qPCR assay (n = 6, ** P < 0.01, *** P < 0.001, Mann–Whitney test). (F)
Western blot assay detected the protein level of IRF7 in eIF4G knockout Caco2 cells, indicating the
successful knockdown of IRF1 detected by western blot. (G) Silence of IRF1 increased the rotavirus
genomic RNA level detected by qPCR assay (n = 6, ** P < 0.01, Mann–Whitney test).
3. Discussion
Many viral mRNAs have acquired a variety of sophisticated strategies to compete with cellular
mRNAs that are already present in the cytoplasm. This allows the selective translation of viral mRNAs,
since they do not possess th required components to initiate the translation of mRNA [23,29]. The
eIF4F initiation factor com lex plays a vital role in initiating translation by recognizing the 5′ cap
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structure in a cap-dependent manner [23]. As the target of numerous cellular signaling pathways,
eIF4F closely controls the translation in response to a multitude of environmental conditions including
viral infection [30]. In contrast, viral infections often cause dysregulation of eIF4F expression to benefit
its replication. Vesicular stomatitis virus (VSV) was reported to cause modifications of the eIF4F
complex to inhibit host protein synthesis [31]. Human Cytomegalovirus (HCMV) replication was
demonstrated to increase the overall abundance of the eIF4F components and promote assembly of the
eIF4F complexes [32]. The cellular cap-dependent protein level was reported to be rapidly inhibited
by foot-and-mouth disease virus (FMDV) via inducing the cleavage of eIF4G [33]. However, we did
not find remarkably altered expression levels of the components of eIF4F, including eIF4A and eIF4E,
upon rotavirus infection (Supplementary Figure S1).
The eIF4F is a tripartite complex composed of three components including a cap-binding subunit
(eIF4E), an RNA helicase (eIF4A), and a large molecular scaffold (eIF4G) that is associated with
eIF3-bound 40S ribosome subunits [30]. These three components of the eIF4F complex were reported
to closely regulate the life cycle of various viruses either promoting or restricting the infection. By
treating influenza virus infected cells with Hippuristanol, a sterol, which is able to suppress RNA
binding, ATPase, and helicase activities to block eIF4A-dependent translation, which demonstrated
that eIF4A fully determines the translation of influenza virus mRNAs [34]; however, eIF4E does not
affect influenza virus protein synthesis [29]. Hepatitis E virus (HEV) requires all three components
of eIF4F to replicate in the host [35]. The protein synthesis of Junin virus (JUNV), Tacaribe virus
(TCRV), and Pichinde virus (PICV) requires the participation of eIF4A and eIF4G but not eIF4E [36].
The eIF4F complex is required for maintaining translation efficiency of HCMV at the start of infection;
while viral protein synthesis becomes increasingly insensitive to inhibition of eIF4F complex at late
stage of virus infection [37]. Cencic et al. demonstrated that blocking the interaction between eIF4E
and eIF4G by a small molecule was capable of remarkably suppressing corovarius replication [24].
Rotavirus mRNAs are capped but not polyadenylated, and its NSP3 is capable of binding to eIF4G
to stabilize the eIF4E–eIF4G interaction [10]. However, knockdown of NSP3 did not influence the
synthesis of viral proteins, indicating that it is not involved in viral mRNA translation and virus
replication [38]. We have previously confirmed that the PI3K-Akt-mTOR pathway sustains rotavirus
infection via its downstream effector 4E-BP1 [39], which provokes us to further investigate the effect of
eIF4E on rotavirus infection, since mTOR exerts the function of splitting the 4E-BP1-eIF4E dimer via
phosphorylating 4E-BP1 [40]. Unexpectedly, we found that blocking the three components of the eIF4F
complex promotes rotavirus infection (Figure 1, Figure 2, Figure 3, and Figure 4). This suggests that
the inhibitory effect of eIF4F on rotavirus might be via another scenario other than the regulating of the
capping process of viral mRNA. PDCD4 is capable of directly inhibiting the helicase activity of eIF4A
by competing its binding to eIF4G to suppress the activity of the eIF4F complex [41]. Consistently,
we found that blocking PDCD4 was capable of inhibiting rotavirus infection (Figure 5), which is in
agreement with the effect of the eIF4F complex on rotavirus infection. Herein, our findings suggest
that the eIF4F complex exerts inhibitory effects on rotavirus infection.
Mounting evidence reveals that the eIF4F complex perverts the interferon signaling pathway
that exerts a pivotal role in defensing various viruses. Viruses often trigger a cascade of events
to activate certain transcription factors, such as IRF3, IRF7, and NF-κB, after being recognized by
pattern-recognition receptors (e.g., Toll-like receptors), which eventually enhances interferon-β (IFN-β)
to exert antiviral effects [27]. It was confirmed that the dephosphorylation of eIF4E was able to stimulate
the NF-κB pathway to promote the production of type I interferon [27]. The eIF4F complex was
demonstrated to closely regulate the translation of STAT1 mRNA [28]. In 4E-BP1−/− and 4E-BP2−/−
double knockout mouse embryonic fibroblasts (MEF), it was found that type-I IFN was strongly
promoted through enhancing the expression of IRF7 mRNA [26]. The binding of eIF4E to eIF4G may
be involved in the translation of IRF7 mRNA [42]. Consistently, we demonstrated that knockdown
and knockout of eIF4E and eIF4G were capable of suppressing the protein level of IRF1 and IRF7
(Figure 6). Importantly, we confirmed that IRF1 and IRF7 per se were able to significantly inhibit
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rotavirus replication (Figure 6). Thus, we have provided a possible novel insight into how the eIF4F
complex regulates rotavirus replication.
In summary, this study has demonstrated that the eIF4F complex can remarkably inhibit rotavirus
infection. The negative regulator of the eIF4F complex, PDCD4, increases rotavirus replication. The
effect of the eIF4F complex on rotavirus replication operates by regulating the expression of certain
antiviral proteins, including IRF1 and IRF7, which exert remarkable antiviral effect against rotavirus.
Hereto, this study revealed a new insight into the regulation of eIF4F on rotavirus replication, and the
eIF4F complex may represent as a promising target for the development of new antivirals and antiviral
therapies against rotavirus infection.
4. Materials and Methods
4.1. Cell Culture and Virus
All cells used in the study were grown in Dulbecco’s Modified Eagle Medium (DMEM, Lonza,
Verviers, Belguim) containing 20% (v/v) heat-inactivated fetal calve serum (FCS) (Hyclone, Lonan,
Utah) and penicillin (100 IU/mL)/streptomycin (100 mg/mL) (P/S) Invitrogen-Gibco) at 37 ◦C in a
humidified 5% CO2 incubator.
Simian rotavirus SA11 was used and prepared as described previously [39,43].
4.2. Inoculation of SA11 Rotavirus in Cells
The inoculation method of SA11 rotavirus was described previously [6,44]. Briefly, cell monolayers
were incubated with SA11 rotavirus (MOI = 0.7) at 37 ◦C with 5% CO2 for 60 min for infection, followed
by removing unbound viral particles by washing with cold PBS three times, followed by adding
culture medium (FCS free) containing 5 µg/mL of trypsin and indicative drugs. Thereafter, cells
were incubated at 37 ◦C in a humidified 5% CO2 incubator. Viral titer was detected by RT-qPCR after
48 h inoculation.
4.3. Real-Time Quantitative Reverse Transcription PCR (RT-qPCR) Analyses
Total RNA was isolated using NucleoSpin®® RNA kit (MACHEREY-NAGEL, Düren,
Germany) according to the manufacturer’s instructions. The extracted RNA was dissolved in
diethylpyrocarbonate (DEPC)-treated water, and its concentration was measured using a Nanodrop
ND-1000 (Wilmington, DE, USA). The 500 ng of total RNA was used for cDNA synthesis using
the reverse transcription system from TAKARA (TAKARA BIO INC) according to manufacturer’s
instructions. The resultant cDNA was diluted and used for evaluating gene expression with
corresponding primers. All RT-qPCR experiments were performed by SYBR-Green-based (Applied
Biosystems SYBR Green PCR Master Mix; Thermo Fisher Scientific Life Scienc; Carlsbad, CA, USA)
real-time PCR with the StepOnePlus System (Thermo Fisher Scientific Life Sciences). The expression of
target mRNAs was normalized to the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA.
The relative mRNA levels of target genes were expressed as 2−∆∆Ct, in which ∆∆Ct = (∆CtTarget
− ∆CtGAPDH)treatment − (∆CtTarget − ∆CtGAPDH)control. Gene primers for RT-qPCR were listed in
supplementary Table S1.
4.4. Gene Knockdown by shRNA
Lentiviral shRNA vectors, targeting eIF4A, eIF4E, eIF4B, and PDCD4 or non-targeted control
lentivirus was prepared in 293T cells in a 6-well-plate using a standard third-generation packaging
system (All shRNA primers were listed in supplementary Table S2).
Cell monolayers were transfected with lentiviral vectors for three days, followed by screening by
puromycin (8 µg/mL) to obtain stable clones, and the knockdown effect was detected by western blot.
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4.5. Gene Knockout by Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas9) Assay
The sgRNAs against eIF4A, eIF4E, eIF4G (primers were listed in supplementary Table S3) were
designed using freely available online tools (https://www.genscript.com/gRNA-database.html).
Oligos were annealed according to the manufacturer’s protocol (37 ◦C for 30 min; 95 ◦C for 5 min and
then ramp down to 25 ◦C at 5 ◦C/min). Subsequently, annealed oligos were ligated into Lenti CRISPR
v2, followed by transforming 10 µL of electrocomp™ cells (ThermoFisher SCIENTIFIC, Carlsbad, USA)
with 5 µL of annealed oligos, and then incubated at 37 ◦C for overnight. 2–3 colonies were picked
up and cultured in LB medium, followed by performing a sequence verification. The verified colony
was expanded in a LB containing Ampicillin culture (100 µg/mL, SIGMA-ALDRICH, Saint Louis,
USA) and DNA was isolated by using DNA extraction kit (ThermoFisher SCIENTIFIC) according
to manufacturer’s protocol. CRISPR DNA was co-transfected with packaging plasmids including
pVSV-G, pMD, and pREV into HEK293T cells and lentiviral vectors were harvested.
Cell monolayers were transfected with lentiviral vectors for three days, followed by screening by
puromycin (8 µg/mL) to obtain stable clones, and the knockdown effect was detected by western blot.
4.6. The 3-(4, 5)-Dimethylthiahiazo (-z-y1)-3, 5-di- Phenytetrazoliumromide (MTT) Assay
MTT assay was used to evaluate cell viability, and the cells were seeded into 96-well plates
(5000 cells/well). Then, the viable cells were quantified at indicated time points by adding 10 µL
5 mg/mL MTT per well, and the cells were incubated for an additional 3 h in a humidified incubator.
Thereafter, medium containing MTT was removed, and a total of 100 µL dimethyl sulfoxide (DMSO)
was added, followed by measuring the absorbance (490 nm) after 50 min inoculation.
4.7. Western Blot
Western blot was described previously [6]. Briefly, cells were lysed using Laemmli buffer
containing 10% dithiothreitol (DTT, Thermo Fisher Scientific, Carlsbad, USA), and then denatured
by heating at 95 ◦C for 5 min. Proteins were detected with antibodies against eIF4A (Cell Signaling
Technology, Danvers, USA), eIF4E (Cell Signaling Technology), eIF4G (Cell Signaling Technology),
PDCD4 (Cell Signaling Technology), and SA11 rotavirus VP4 (provided by professor Harry Greenberg,
Stanford University School of Medicine, USA). The bound antibodies were visualized with Odyssey
(LI-COR Biosciences, USA). The β-actin (Santa Cruz) was used as a loading control.
4.8. Statistics
All numerical results are reported as Mean ± Standard Error of Mean (SEM). The statistical
significance of differences between means was assessed with the Mann–Whitney test using GraphPad
Prism 5 (stationary-pc/mac version; GraphPad Software Inc., La Jolla, CA, USA). The statistical
significance was defined as P ≤ 0.05.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/7/
1580/s1.
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